Physician profile
Michael Paul Ast
NPI 1427204106
$1,316,815.20
in general payments reported to CMS, 2019-2025
21 companies · $346K in 2025
The $346K reported for 2025 was more than what 99% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171K · 2020: $92K · 2021: $83K · 2022: $101K · 2023: $169K · 2024: $355K · 2025: $346K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $521K · Consulting Fee: $233K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $64K · Travel and Lodging: $33K · Food and Beverage: $14K · Education: $5,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $520,582.65 |
| Consulting Fee | $233,228.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $64,100.00 |
| Travel and Lodging | $33,420.74 |
| Food and Beverage | $13,528.47 |
| Education | $5,400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orthalign INC | $623,781.57 | 2019-2025 | Orthalign Plus |
| Smith+Nephew, INC. | $506,226.69 | 2019-2025 | Real Intelligence, Journey II, Tandem |
| Stryker Corporation | $129,501.23 | 2019-2024 | Mako, Triathlon, Insignia |
| Solventum Corporation | $10,200.00 | 2024 | Prevena, Prevena Restor Arthroform, 3m Ioban |
| Vertex Pharmaceuticals Incorporated | $9,950.00 | 2025 | |
| Ignite Orthomotion LLC | $9,000.00 | 2023-2024 | |
| Kci USA, INC. | $6,564.81 | 2019-2023 | Prevena, Prevena Restor Arthroform, Promogran Prisma |
| Heron Therapeutics, INC. | $5,794.75 | 2019-2025 | Zynrelef |
| Zimmer Biomet Holdings, INC. | $5,679.69 | 2021-2024 | Rosa, Comprehensive Shoulder System |
| Medical Device Business Services, INC. | $2,570.07 | 2022-2024 | Attune |
| Convatec INC. | $2,275.00 | 2022 | |
| Conformis, INC. | $1,944.08 | 2019-2022 | |
| Bioventus LLC | $1,795.03 | 2021 | |
| Depuy Synthes Sales INC. | $449.25 | 2019-2025 | Velys, Attune, Reclaim |
| Pacira Therapeutics, INC. | $310.92 | 2019-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $193.08 | 2019-2020 | |
| Davol INC. | $185.66 | 2023 | Arista Ah Flexitip |
| Horizon Therapeutics Plc | $141.67 | 2019 | |
| Engage Uni, LLC | $114.00 | 2020 | |
| Linvatec Corporation | $91.45 | 2024 | Biobrace 23mm |
| Maxx Orthopedics, INC. | $46.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ast listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.